Umbelliferone Inhibits Zika Virus (ZIKV) NS5 Activity and Replication In Vitro

Area of Science:

• Virology
• Drug Discovery
• Medicinal Chemistry

Background:

• Zika virus (ZIKV) poses a significant global health threat.
• Existing treatments for ZIKV are limited.
• Understanding ZIKV replication mechanisms is crucial for therapeutic development.

Purpose of the Study:

• To investigate the potential of umbelliferone as an antiviral agent against ZIKV.
• To elucidate the mechanism of action of umbelliferone against ZIKV.
• To identify the specific viral target of umbelliferone.

Main Methods:

• In vitro antiviral assays to assess ZIKV replication inhibition.
• Cytotoxicity assays to determine umbelliferone's safety profile.
• Time-of-drug-addition assays to pinpoint the stage of viral inhibition.
• In silico molecular docking to predict drug-target interactions.
• In vitro enzyme assays to confirm target engagement.

Main Results:

• Umbelliferone inhibited ZIKV replication in vitro without causing cytotoxicity.
• The C7 hydroxyl group of umbelliferone was essential for its antiviral activity.
• Umbelliferone acted at a postentry stage of the ZIKV life cycle, after polyprotein processing.
• Molecular docking and in vitro assays identified ZIKV NS5 as the direct target of umbelliferone.
• Umbelliferone disrupted ZIKV NS5 activity.

Conclusions:

• Umbelliferone is a potent inhibitor of ZIKV NS5 activity and replication.
• The findings support umbelliferone's potential as a lead compound for anti-ZIKV drug development.
• Further research into umbelliferone derivatives may yield novel therapeutic strategies against ZIKV.